Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Gyre Therapeutics Inc.

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.